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Age-associated endothelium dysfunction is a major risk factor for the development of cardiovascular diseases. Endothelium-
synthesized prostaglandins and thromboxane are local hormones, which mediate vasodilation and vasoconstriction and
critically maintain vascular homeostasis. Accumulating evidence indicates that the age-related changes in endothelial eicosanoids
contribute to decline in endothelium function and are associated with pathological dysfunction. In this review we summarize
currently available information on aging-shifted prostaglandin proﬁles in endothelium and how these shifts are associated with
cardiovascular disorders, providing one molecular mechanism of age-associated endothelium dysfunction and cardiovascular
diseases.
1.Introduction
Cardiovascular disorders, including atherosclerosis, corona-
ry artery disease, heart failure, and hypertension, remain
the leading cause of death worldwide [1]. These diseases are
among several pathological conditions that are associated
with aging [2–4], and age is a primary risk factor for their
development [5, 6]. Endothelium is a thin layer of epithelial
cells which line the interior of lymph and blood vessels and is
a major component of the vascular wall. One important con-
tributor to the development of cardiovascular diseases is a
dysfunctional endothelium. Endothelial dysfunction is con-
sidered a fair predictor of cardiovascular diseases [4, 7–11].
Furchgott and Zawadzki unequivocally demonstrated
that the endothelium is required for normal vessel relaxation
[12]. Besides inducing relaxation, normal and healthy endo-
thelium regulates vessel wall permeability, blood ﬂow, vas-
culartone,andstructureandexertsanticoagulantandﬁbrin-
olytic properties [13]. Aging adversely aﬀects these normal
functions of the endothelium, enhancing vasospasm and
thrombosis, leading to eventual cardiovascular diseases [4,
14–16]. Age-impaired vascular relaxation has been shown
in diﬀerent human vascular beds including brachial artery,
aorta, coronary artery, carotid, and mesenteric microvessels
[14–21]. In line with these reports, additional evidence has
been obtained in diﬀerent vascular beds of animals including
dogs [2, 22], rats [2, 23–32], and mice [33, 34]. This re-
duced relaxation is accompanied with increased blood pres-
sure [35–39]. Elevated blood pressure is an important cardi-
ovascular risk factor that can eventually lead to heart failure.
Normal endothelial function is regulated by a controlled
balance between endothelium-dependent relaxing factors
and endothelium-dependent contracting factors. The main
vasoactivefactorsreleasedbyendothelialcellsarenitricoxide
(NO) and cyclooxygenase- (COX-) derived eicosanoids [4,
40, 41]. NO production has been shown to be reduced with
aging [42–45]. There is less information on how eicosanoids
change in the endothelium with age. It is also not well under-
stood how changes in eicosanoid proﬁle might contribute
toendotheliumdysfunction.Nevertheless,accumulatingevi-
dence indicates that the age-related changes in endothelial
eicosanoids contribute to endothelium dysfunction and to
the development of age-associated cardiovascular diseases.
In endothelium, there are six primary cyclooxygenase-
(COX-) derived eicosanoids, prostaglandin H2 (PGH2),
prostaglandin I2 (PGI2, prostacyclin), prostaglandin E2
(PGE2), prostaglandin F2α (PGF2α), prostaglandin D2
(PGD2), and thromboxane A2 (TxA2)( Figure 1). These ei-
cosanoids are local hormones that are synthesized by vir-
tually all mammalian tissues [46]a n da c ta to rn e a rt h e i r2 Journal of Aging Research
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Figure 1: Synthesis and signaling of PGs in the vascular sys-
tem. Upon stimulation, AA is released from the endothelial cell
membrane to the cytosol where it is enzymatically converted to
PGH2 by COX1 and COX2. Subsequently, PGH2 is transformed to
PGI2,P G E 2,P G D 2,P G F 2α, and TxA2. These substances, as well as
untransformed PGH2, are released out of endothelial cells and into
the circulation, where they interact with their receptors localized on
the smooth muscle cell surface and trigger vasoactive signals.
sites of synthesis in both autocrine and paracrine fashion.
They trigger a vast array of biological signals, among which
are vasodilation, vasoconstriction, and platelet aggregation
[47–49]. In fact, the eicosanoids were the ﬁrst identiﬁed
endothelium-derived vasoactive factors [50, 51]. Although
there is conﬂicting evidence [52–54], the majority of the lit-
erature shows that PGI2 and PGD2 are vasodilators [55–59],
whereasPGH2,P G F 2α,a n dT x A 2 are vasoconstrictors and/or
platelet aggregation inducers [53, 54, 60–66]. PGE2 can in-
duce vasodilation [47, 67–70]o rv a s o c o n s t r i c t i o n[ 53, 54,
71–73], depending on the vascular bed and concentration
[74, 75]. In healthy endothelium, these vasodilators and
vasoconstrictors, coexisting with other vasoactive factors, are
held in balance to maintain normal vascular functions. The
aging process shifts this balanced proﬁle toward a pro-
constrictive mediator proﬁle [76, 77]. In this paper, we sum-
marize and discuss how endothelium-derived eicosanoid
proﬁle changes with age and how those changes might con-
tribute to age-associated endothelium dysfunction.
There is limited data on how eicosanoids change in hu-
mans [4], and most experiments have been conducted in
animal models and most commonly in rat [2]. Rats of 1.5–2
months or less are considered immature, rats of 3–6 months
are considered young adult, and rats of approximately 24
months or more are considered aged, though there are dif-
ferences between strains [2].
2. Cyclooxygenases andPGH2
There are two isoforms of the cyclooxygenases (COX1 and
COX2) encoded by two diﬀerent genes. Both COX1 and
COX2 are expressed in the endothelial and vascular smooth
muscle cells, and the expression levels are 20-fold higher in
endothelial cells than in smooth muscle cells [78]. In en-
dothelium, both of the COX enzymes are constitutively ex-
pressed [79, 80]. However, they are also inducible, for in-
stance, by shear stress [79–81]. Endothelial cells express
COX1 preferentially over COX2 [82, 83].
In human mesenteric microvessels of individuals greater
than 80 years of age, COX1 levels are 50% increased, while
COX2levelsareslightlydecreased[21].Innormotensiverats,
both COX1 and COX2, in either whole vascular tissue or en-
dothelial cells from vasculatures, are increased with aging
from 1-fold to 5-fold [29, 42, 63, 84–86]. Comparable eﬀects
of aging on COX1 and COX2 expression levels have been ob-
served in mice [33, 34]. At similar ages, COX1 or COX2
expression, measured at the mRNA or protein levels, is
almostdoubledintheaortaofspontaneoushypertensiverats
(SHRs) as compared to normotensive control Wistar-Kyoto
(WKY) rats [63, 84, 87, 88]. Similar increases in COX1 and
COX2 were observed in Nω-nitro-L-arginine methyl ester-
(L-NAME-) induced hypertensive rats as compared to con-
trol Sprague-Dawley rats [89]. Increased COX2 was also re-
portedintherenalarteryofhypertensivepatients[89].These
data indicate that there are age-associated increases in COX1
and COX2 levels, as well as an association between elevated
COX1/COX2 levels, in both animal models and human
studies, and clinical cardiovascular disorders.
Uponstimulation,arachidonicacid(AA)isreleasedfrom
the cell membrane to the cytosol where it is enzymatically
converted to PGH2 by COX1 and COX2 (also referred to as
synthase, PGHS1, and synthase 2, PGHS2, resp.). As shown
in Figure 1,P G H 2 is the common precursor of other pros-
taglandins and TxA2.I ti st r a n s f o r m e dt ov a r i o u sP G sa n d
TxA2 by a corresponding speciﬁc terminal synthase. Besides
serving as a common precursor, untransformed PGH2 can
trigger signals such as vasoconstriction and platelet aggrega-
tion by interacting with TxA2 receptor (TP) [25, 26, 90–99].
Although no evidence has directly shown the attenuation
of untransformed and bioactive PGH2 during aging or in
cardiovascular pathology, likely due to instability and diﬃ-
culty in measurement [25, 26, 91, 92, 95, 96], increased
COX1 and COX2 associated with aging [21, 29, 42, 63, 84–
86] and hypertension [63, 84, 87, 88] would be predicted to
resultinincreasesinuntransformedPGH2.Indirectevidence
is provided by reports of reduced vasoconstriction of aortas
of aged and/or hypertensive rats by inhibitors of PGH2 syn-
thases, rather than TxA2 synthase (TXS) [25, 26, 91, 92, 96].
AlthoughthevascularcontractioninducedbyAAhasmainly
been attributed to TxA2 [100, 101], the eﬃcacy of PGHS in-
hibition, but poor eﬃcacy for a TXS inhibitor, in inducing
relief from vasoconstriction provides evidence for PGH2 as a
vasoconstrictor [91, 92, 96].
3.PGI2
PGI2 (prostacyclin) is the ﬁrst described metabolite of
arachidonic acid, and endothelium is the major site of
its biosynthesis [51, 57]. In endothelium, both COX1 andJournal of Aging Research 3
COX2 are the upstream contributors of PGI2 synthesis [80,
102–104]. PGI2 is synthesized by its terminal speciﬁc PGI2
synthase (PGIS)[105, Figure 1]. PGIS colocalizes with COX1
in endothelial cells [106]. In endothelium, PGIS is by far
the most abundant PG terminal synthase, with its expression
level 5–100-fold higher than the other PG terminal synthases
[54, 64, 65, 84]. Accordingly, PGI2 is the most abundant
endothelial eicosanoid, with expression levels 10–100-fold
higher than that of the other eicosanoids in humans [107,
108] and in animals [54, 97, 109, 110].
PGI2 triggers potent vasodilation [51, 57] by interacting
with the PGI2 receptor (IP) (Figure 1), which located in
smooth muscle cells [108, 111]. The vasodilation eﬀect of
PGI2 has also been shown in pig coronary arteries at low
concentrations [58]. At higher concentrations PGI2 may
induce vasoconstriction [32, 54, 64]. PGI2 cannot cause
vasoconstriction until its concentration reached 1μMo r
higher. 1μM is 1000-fold higher than the endogenous conc-
entration of PGI2, which is in the 0.2–1nM range [112].
Even at elevated concentrations, PGI2 is a weak vasocon-
strictor and induces modest tension in the rat aorta
[32, 54, 64]. Modest vasoconstrictive eﬀects of PGI2 may
emanate from weak cross-activation of TP, which can in-
duce vasoconstriction [49]. At lower concentrations, PGI2,
especially endogenous PGI2, is a vasodilator. In addition,
PGI2 is the most potent endogenous anticoagulation agent
[113]. The vasodilation and anticoagulation eﬀects of PGI2
have been conﬁrmed by a recent report showing that
IP deletion in mice results in hypertension and reduced
anticoagulation activity [114].
In human blood, PGI2,m e a s u r e da sP G F 1α, is 400pg/mL
innewborninfants,230pg/mLininfants,150pg/mLinado-
lescents, and 85pg/mL in adults [112]. Age-associated PGI2
decline is also observed in urine of humans [115, 116]. The
endothelium is the main site for PGI2 synthesis [50, 51]. Al-
though there has been no report on PGI2 production in iso-
lated human vessels, PGI2 levels were reported to decline in
cultured human vascular endothelial cells during serial pas-
sage [117–119]. Based on these reports, one would expect
that PGIS in endothelium decreases with age. Yet there have
been no reports evaluating age-associated PGIS changes in
the human endothelium. In the endothelial cells from rat
aorta, there is a slight and insigniﬁcant age-associated de-
crease in PGIS mRNA [84]. However, additional evidence
shows that mRNA or protein of PGIS is 2–4-fold higher
in aorta or coronary arteries of aged normotensive rats
[85, 86, 110, 120] suggesting that lower PGI levels may be
caused by increased PGI2 degradationwith age, rather than
the change in PGI2 synthesis. In fact, there is no apparent
correlation between circulating PGI2 level with level of en-
dothelial PGIS, suggesting the necessity of investigation of
the eﬀects of age on the metabolism/degradation of PGI2.
More work is needed to determine whether circulating PGI2
correlates to endothelial PGI2 and to clarify the eﬀects of
age on PGI2 in the endothelium and in the circulation.
Age-associated reduction in IP level has been consistently
reported in rats [84, 85]. The reduced IP is expected to lead
toreducedsensitivitytoPGI2 eﬀects.Consistently,dilationin
response to PGI2 is signiﬁcantly blunted in aged humans as
determined by forearm blood ﬂow measurements [121].
Reports on the change in PGI2 or PGIS under patholog-
ical conditions, such as hypertension, are contradictory.
While one group reported a 50% reduction in PGI2 in
SHR aorta as compared to WKY aorta [96], another group
reported insigniﬁcant diﬀerences in PGI2 levels in SHR and
WYKrats[64,65].Inaddition,TangandVanhouttereported
that PGI2 mRNA is 4-fold higher in the endothelial cells
of SHR aorta than in WKY aorta [84]. These limited and
inconsistent reports indicate a need for more complete and
thorough investigations into how aging aﬀects PGI2, its sy-
nthase, receptor, and metabolism. Moreover, clarifying PGI2
eﬀects in the development of cardiovascular disorders in ani-
mal models and in humans could be of potential therapeutic
signiﬁcance.
4.PGE2
Prostaglandin E2 (PGE2)is the most abundantprostaglandin
in the human body. In endothelium, however, its level is low-
er than that of PGI2, in line with a lower expression level
of the corresponding synthases, which are 5–100-fold lower
than PGIS [54, 64, 65, 84]. There are three types of known
PGE2 synthases (PGESs), the cytosolic PGES (cPGES) and
two forms of membrane PGES, mPGES1 and mPGES2
[122, Figure1]. cPGES is constitutively expressed and func-
tionally coupled to COX1 [122, 123]. mPGES1 is inducible
and functionally coupled with COX2 [124] and is the ma-
jor PGE2 synthase responsible for PGE2 production [123].
In endothelium, the expression levels of the PGESs are com-
parable to other PG synthases [54, 64, 65, 84]. Consistently,
the amount of PGE2 in endothelium is comparable to other
PGs, but lower than the amount of PGI2 [54, 97, 107–
110, 125]. In further accord, the contribution of PGE2 to en-
dothelium-dependent vasoaction is marginal [84, 125].
Chen et al. showed that deletion of mPGES1 in mice result-
ed in abolished production of PGE2 but did not aﬀect blood
pressure [114]. Yang, on the other hand, showed that
mPGES1 deletion in mice resulted in exaggerated hyperten-
siveinresponsetohighsaltandangiotensinIIinfusion[126],
suggesting that mPGES1 may be an important physiological
regulator of blood pressure. While the role of mPGES1 in
blood pressure regulation is debatable, mPGES1 is implicat-
ed in atherosclerosis. Deletion of mPGES1 in mice retards
atherosclerosis development [127].
PGE2 acts through four PGE2 receptors (EP1, EP2, EP3,
and EP4), which are mainly located in the smooth muscle
cells in the vessels [125, 128, Figure1]. Activation of EP1
and EP3 receptors induces calcium mobilization/release and
inhibits adenylyl cyclase release, which triggers vasoconstric-
tions [111, 129]. In contrast, activation of EP2 and EP4
receptors stimulates adenylyl cyclase and induces cyclic ade-
nosine monophosphate release, which triggers vasorelaxa-
tion [111, 129]. The vascular actions of PGE2 are complex
due to the opposing vasoactions triggered by the binding of
PGE2 to the variant PGE2 receptors. Depending on the cir-
cumstances, PGE2 may be vasodilating [47, 67–70]o rv a s o -
constricting [53, 54, 71–73]. In addition to the distributions4 Journal of Aging Research
of diﬀerent PGE2 receptors expressed in the vascular system,
PGE2 concentration is also important. This complexity likely
explains the reported inconsistent eﬀects of mPGES1 dele-
tion on blood pressure [114, 126]. PGE2 has a biphasic eﬀect
on human blood platelet aggregation. At low concentrations
(0.01–1μM), it potentiates platelet aggregation, and, at high-
er concentrations (10μM), it inhibits ADP- and collagen-in-
duced aggregation in platelet rich plasma [71, 130–132]. The
endogenous PGE2 concentration is below 1μM[ 133], mak-
ingPGE2 astimulatorofatherosclerosis.Thus,reducedPGE2
level by mPGES1 deletion retards atherosclerosis develop-
ment [127].
There is little information available on age-related chan-
ges in any of the PGESs, PGE2,o rE P s .Ar e c e n tr e p o r tb y
Tang and Vanhoutte revealed that while cPGES and mPGES1
intheaortaendothelialcellsareinsigniﬁcantlyhigherinaged
rats, mRNA of mPGES2 is 5-fold higher [84], which can
presumably result in higher level of PGE2.P G E 2 secreted
fromcoronaryarteriesisincreasedinagedratascomparedto
young rats [120]. Expression of EP1–4 increased with age,
with EP4 elevated 2-fold in endothelial cells from rats of 72
weeks as compared with rats of 36 weeks [84]. Since vaso-
action depends on the ligand and the type of receptors, age-
increased PGE2 and EP4 are assumed to predispose to in-
creased vasodilation. Further investigation is required to
determine the eﬀect of age-related changes in PGE2 and its
synthases and receptors in diﬀerent vascular beds and on re-
laxation/constriction of vasculatures.
5.PGF2α
There are two isomers of prostaglandin F2α. One is PGF2α,
and the other is 9α,1 1 β-PGF2 [134–137]. They are trans-
formed from PGH2 by the membrane-associated 9,11-endo-
peroxide reductase and from PGD2/PGE2 by cytosolic PGD2
11-ketoreductase/PGE2 9-ketoreductase, respectively [138,
Figure1]. In endothelium, the level of PGF2α is similar to
that of PGE2, but much lower than that of PGI2 [54, 97, 107–
110,125],correspondingtolowabundanceofPGF2α cognate
synthase (PGFS) in the endothelium [54, 64, 65, 84].
PGF2α has its own speciﬁc receptor (FP), which is ex-
pressed in endothelium and in vascular smooth muscle cells
[139–143, Figure 1]. PGF2α can also interact with TP [54].
Interaction between PGF2α and its receptor generates cal-
cium release and triggers potent vasoconstriction [144–148].
Deletion of FP reduces arterial blood pressure and delays
atherogenesis in hyperlipidemic mice [149]. PGF2α has also
beenindicatedinpromotingcardiachypertrophy[150–152].
AlthoughPGF2α is a potent vasoconstrictor, the contribution
ofPGF2α toendothelium-dependentcontractionsisminimal
in most cases due to its relatively low abundance in the
endothelium [54, 97, 107–110, 125].
Information on the eﬀects of aging on PGF2α is limited.
PGFS mRNA was doubled in the endothelial cells from aged
rat aorta as compared to that from young rat aorta [84].
Consistently, PGF2α is 2-fold higher in the aorta of aged
rats versus young rats [110, 148]. Change in FP mRNA in
the endothelial cells of rat aorta with age, however, is in-
signiﬁcant [84]. Basal PGF2α is slightly higher in the aorta of
SHRs than that of WKY rats, but the diﬀerence is increased
upon acetylcholine stimulation [54]. Research needs to be
conducted to obtain more complete information on age-
associated changes in PGF2α in humans and the eﬀects
of those changes on the development of cardiovascular
disorders.
6.PGD2
PGD2 is synthesized by two PGD2 synthases (PGDSs) encod-
ed by two unrelated genes. One is hematopoietic PGDS (H-
PGDS), and the other is lipocalin-type enzyme (L-PGDS)
[138, Figure 1]. Both can be upregulated in response to an
increase in ﬂuid shear stress [153]. In most of the vascula-
tures, the level of PGD2 is very low or undetectable in some
vascular beds [74], due to the low level of PGDSs [54, 64, 65,
84].
PGD2 has multiple receptors [154]. However, two PGD2
receptors (DP1 and DP2) have been most widely studied
(Figure 1). Besides playing an important role in the central
nervous and immune systems [154], PGD2 has functions
in the vasculature. PGD2 can elicit endothelium-dependent
relaxation through receptor activation [59] and acts as a va-
sodilator [155, 156]. On the other hand, it can also act as
a bronchoconstrictor [157–159]. Finally, PGD2 is an anti-
coagulant [160–163].
There is only one report on the eﬀect of aging on PGDS
and DP. While aging had no eﬀect on L-PGDS, it caused a 5-
foldincreaseinH-PGDSmRNAinagedrataortaendothelial
cells [84]. Age had no apparent eﬀect on DP [84]. H-PGDS
is 3-fold higher in aorta endothelial cells from SHRs versus
WKY rats, whereas L-PGDS is decreased in these cells in
SHRs versus WKY rats [84]. In the smooth muscle cells from
the same aorta preparations, DP mRNA was measured to be
3-fold higher in SHRs as compared with WKY rats [84].
7.TxA2
TxA2 is mainly produced in the platelets [100, 101]. It is also
synthesized in the vasculature, the endothelium, and smooth
muscles by TxA2 synthase (TXS) [49, Figure 1]. However,
the amount of TxA2 in the endothelium is much lower than
the amount of PGI2 [54, 97, 107–110, 125]. Consistently, the
expression level of the TXS is much lower than that of PGIS
[54, 64, 65, 84].
There are two types of TxA2 receptors (TP) denoted, TPa
and TPb. TP interacts with TxA2 and other PGs, although
TxA2 is the most potent agonist [54, 164, Figure 1]. TP
appears to be the main receptor of PGH2 [25, 26, 90–
97]. Deletion of TP receptors has provided insights into
their physiological function. For example, TP knochout
mice exhibit decreased vascular proliferation and platelet
activationinresponsetointimallesions[165].Theseanimals
also experience delays in atherogenesis [166]. TP deletion
also prevents angiotensin-II- and L-NAME-induced hyper-
tension and associated cardiac hypertrophy [167].
TxA2 elicits diverse physiological/pathophysiological re-
actions, including platelet aggregation and vascular smooth
muscle contraction [49]. Activation of platelet aggregationJournal of Aging Research 5
Table 1: Age-associated changes in PGs and TxA2 and their synthases and receptors.
Entity Tissue Age Change References
COX1/2 (hum, r, m) Mesenteric microvessels Adult, aged Increase
[21, 29, 33,
34, 42, 63,
84–86]
PGI2 (hum) Blood Adolescent, aged Decrease [112, 116]
PGIS (r) Aorta, coronary artery in heart Adults, aged Increase [85, 86,
110, 120]
IP (r) Aorta Adults, aged Decrease [84, 85,
121]
PGE2 (r) Coronary artery in heart Aged Increase [120]
cPGES (r), Aorta Old adult N/S [84]
mPGES-1 (r) Aorta Old adult N/S [84]
mPGES-2 (r) Aorta Old adult Increase [84]
EP1–3 (r) Aorta Old adult N/S [84]
EP4 (r) Aorta Old adult Increase [84]
PGF2α (ham, r) Aorta Aged Increase [110, 148]
PGFS (r) Aorta Old adult Increase [84]
FP (r) Aorta Old adult N/S [84]
PGDS (r) Aorta Old adult Increase [84]
DP (r) Aorta Old adult N/S [84]
TxA2 (r) Aorta or mesenteric artery Increase [42, 86,
172]
TXS (r) Aorta Old adult Increase [84]
TP (r) Aorta Old adult N/S [84]
hum: human; ham: hamster; r: rat; m: mouse; N/S: not signiﬁcant.
Deﬁnition of age groups: human, adolescent, 13–19 years; adult, 20–60 years; aged, >60 years. Hamster, aged, >18 months. Rat, young adult, 3–6 months; old
adult, 6–18 months; aged >24 months.
is thought to be the dominant biological function of TxA2.
TxA2 causes platelet shape change, aggregation, and secre-
tion, which promotes thrombus formation and throm-
bosis [168–171]. Thrombosis can cause acute myocardial
infarction and atherogenesis [166, 171–174]. TxA2-induced
contraction eﬀects are variable, depending on the speciﬁc
vascular beds examined and the agent used to induce con-
traction [116, 175, 176]. The majority of reports coincide
with the view that the contraction induced by endothelium-
derived TxA2 is weak, because inhibitors of TXS do not in-
ducerelaxation[91, 92, 96, 176].Contractioneﬀectsarelike-
ly mediated by TP activated by PGH2 because inhibitors of
PGHSs and TP induce relaxation [91, 92, 96, 175, 176].
Several publications reported a 2–5-fold increase in TxA2
in aorta or mesenteric arteries of aged rats as compared to
that of young rats [42, 86, 172]. Consistently, Tang and Van-
houtte reported a 4-fold increase in TXS mRNA [84]. In
contrast, a single investigation of age-dependence of TxA2
didnotﬁndanysigniﬁcantdiﬀerenceinTxA2 betweenyoung
and aged rat aortas [110]. Aging did not show any signiﬁcant
eﬀect on rat aorta TP mRNA [84].
An increased production of TxA2 has been found in pa-
tients and animal models of several cardiovascular diseases
including unstable angina [177], experimental myocardial
ischemia and infarction [178], cerebral vasospasm, preg-
nancyinducedhypertension[179,180],andcongenitalheart
disease [116]. TxA2 levels reported in those studies are
systemic, rather than endothelial. In endothelium, there is
no diﬀerence in aorta TxA2 between SHRs and WKY rats
[54, 64, 65, 87]. However, TXS mRNA is doubled in the aorta
endothelium of SHRs versus WKY rats [84]. Age-related
changes in TP have not been found [84, 181].
Insummary(Table 1),aginghasbeenconsistentlyshown
to cause severalfold increase in COXs, that is, the synthesis of
PGH2 [29, 42, 63, 84–86]. Aging probably reduces PGI2, the
predominant PG in the endothelium [112, 115–118, 182],
though it is not certain and requires more work. Aging has
been shown, or has the potential, to change other PGs in the
endothelium. However, because the level of PGI2 is 10–100-
fold higher than that of the rest of PGs, the shift of PG proﬁle
in the endothelium during aging will be predominantly
determined by PGI2 and untransformed PGH2.P G I 2 and
PGH2 have opposing eﬀects on vessels and platelets. The
net result of the eﬀects of aging will be a shift toward a
proconstrictive mediator proﬁle, as shown in Figure 2.
8.Associationof Prostaglandinand
CardiovascularDisordersinAging
Associated with this shift are several cardiovascular dis-
orders including hypertension, atherosclerosis, myocardial
ischemia, myocardial infarction, and stroke (Figure 2(b)).6 Journal of Aging Research
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Figure 2: Age-shifted PG proﬁle (a) and vasoaction (b). (a) As age advances, most of the PGs and TxA2 increase, whereas PGI2 decreases.
(b) The age shifts PG proﬁle toward vasoconstriction and coagulation causing several cardiovascular disorders.
Table 2: Prostaglandin-related pharmacological agents in the treatment of cardiovascular diseases.
Modulator Drugs (trade name) Clinical application References
PGI2 and its stable analogues
Epoprostenol sodium (Flolan), Beraprost
sodium (Procyclin), Iloprost (Ventavis),
Treprostinil (Remodulin)
Primary pulmonary hypertension,
pulmonary arterial hypertension [200–207]
PGE2 and its analogues Dinoprostone, Viprostol Congenital heart disease [208–210, 214–
217]
TXS inhibitors Dazoxiben, Camonagrel, Picotamide
(Dusodril) Thrombosis, atherosclerosis, arrhythmias [218–226]
TP inhibitors Picotamide, S18886 (Triplion) Thrombosis, atherosclerosis, ischemic
stroke, myocardial infarction [84, 223–227]
COX1 inhibitor Aspirin Thrombosis, atherosclerosis, ischemic
stroke, myocardial infarction [231–235]
Reduced ratio of PGI2/TxA2 was observed in elderly hyper-
tensive patients [183–186]. Age impaired PGI2 synthesis
[84, 187] is associated with hypertension [84], progression
of atherosclerotic lesions [188], and increased thrombotic
risk and heart failure [189, 190]. In addition, aging not
only reduces the expression of IP [84], but also reduces the
sensitivity of IP [182, 191]. These factors might contribute
to the progression of atherosclerosis, as mice with deleted IP
[192, 193] and human patients with a dysfunctional pros-
tacyclin IP receptor mutation [194] show accelerated athero-
thrombosis [97].
On the other hand, aging induces TXS [84]. Higher con-
centrations of TxA2 are observed in serum or urine in several
age-related and hypertensive diseases [185, 186, 195]. In
the atherosclerotic coronary artery, the density of TP recep-
tor is increased [171]. Aging-increased TxA2, together with
induced TP in the atherosclerotic coronary artery, accel-
erates arterial atherosclerosis, leading to myocardial in-
farction [191]. The TP-mediated signaling can also be trig-
gered by PGH2. Age increases COX1/2 in animals and hu-
man [21, 29, 33, 34, 42, 63, 84–86] and thereby increases
PGH2 production. Age-increased expression of COX-2 in
coronary, carotid, and femoral arteries is associated with hu-
man atherosclerosis [196–199].
9. Therapeutics That Modulate Prostaglandins
inCardiovascularDisorders
Because prostaglandins and thromboxane are such impor-
tant factors in endothelium functions and therefore in the
physiology and pathology of the vascular system, numerous
pharmacological agents that target these factors have been
developed to mitigate cardiovascular diseases. As listed in
Table 2, prostacyclin (PGI2) and analogues are used clinically
to treat hypertension, especially pulmonary hypertension
[75, 200–202]. They are also used to inhibit arterial throm-
bosis and ameliorate myocardial ischemia [203–207]. Al-
though the vascular actions of PGE2 are complex, PGE2 and
analogues are used to reduce blood pressure and to alleviate
congestive heart failure [208–210], owing to their ability to
stimulate renin release and natriuresis and diuresis [211–
213]. PGE2,P G E 1, and their analogues are more often used
to maintain the patency of the ductus arteriosus in infants
with congenital heart disease [214–217]. Antagonists of TXS
and TP are potent antithrombosis agents and used to treat
atherosclerosis, myocardial ischemia, and stroke [218–227].
The underlying principle of the design of these drugs is
to selectively increase the eﬀects of vasodilators and anti-
coagulators and to selectively reduce the eﬀects of vasocon-
strictors and coagulators by modulating the amount of li-
gands, synthases, or receptors of a speciﬁc eicosanoid. Be-
causeprostaglandins and thromboxane A2 are fromthe same
precursor but elicit opposing eﬀects, selectivity is crucial
in the design of these therapeutics. Nonselective inhibition
of the upstream synthases, COX1 and COX2, can result in
u n d e s i r a b l es i d ee ﬀects including hypertension, manifesta-
tion of myocardial ischemia, and increased incidents of acute
myocardial infarction and stroke, which occur more often in
the elderly [104, 228–230].Journal of Aging Research 7
Intriguingly, low dose of aspirin, an inhibitor of COX1, is
popularly used in the prevention of cardiovascular diseases
[231–233]. Aspirin covalently acetylates a speciﬁc serine
moiety (serine 530 of COX-1 and serine 516 of COX-2)
[234, 235], and its binding to COX1 is about 170-fold
stronger than that to COX-2 [236]. Thus, aspirin is a cova-
lent inhibitor of COX1 inactivating it irreversibly. TxA2 is
mainly produced in platelets [100, 101], whereas PGI2 is
mainly produced by endothelial cells [51, 57]. Diﬀerent
from most other cell types, platelets do not possess nuclei,
which are required for protein synthesis. While COX1 can
be regenerated in other cells, such as endothelial cells, COX1
cannot be regenerated in platelets. Nor can COX1 activity be
recoveredafterinactivationbyaspirin.Therefore,lowdoseof
aspirin irreversibly and selectively inhibits TxA2 production
in platelets.
However, new platelets are constantly formed, and TxA2
is persistently produced [237], which leads to a need for
continuous dosing to constantly inhibit COX1. Aspirin res-
istance is a common clinical phenomenon [238] and has
been observed for more than twenty ﬁve years [239].
Aspirin resistant patients, partially due to inherited poly-
morphisms in COX1 [240, 241], have a nearly 4-fold
increase in risk of suﬀering a vascular event compared
with aspirin responders [242–244]. As an alternative to
aspirin therapy, antagonists of TXS and TP, which can also
be combined with aspirin, have been applied to ameliorate
thrombosis and prevent cardiovascular diseases [226].
10. Conclusion andPerspective
The incidence and prevalence of cardiovascular diseases in-
crease with advancing age, to the extent that age has been
identiﬁed as the dominant risk factor for these pathologies
[2, 4–6]. It is well established that PGs are powerful endo-
genous vasodilators and vasoconstrictors and platelet aggre-
gators, playing important roles in regulating homeostasis in
vascular systems. Although limited, the current analysis of
the literature suggests that there is a modiﬁed PG proﬁle as-
sociated with age and indicates that age has signiﬁcant ef-
fects on the abundance of PGs, their synthesis, as well as
their signaling transduction pathways. Aging-modulated PG
proﬁle oﬀers a potentially important molecular mechanism
underlying age-dependent endothelial dysfunction and age-
associated cardiovascular diseases. Knowledge of age-as-
sociated PGs proﬁle changes can be important for designing
new pharmacological interventions to prevent or slow down
age-associated cardiovascular diseases. Given their biological
roles,improvedinvestigationofage-associatedchangesinPG
synthesis, metabolism, and signaling in all major vascular
beds is needed.
It is clearly diﬃcult to obtain human vascular tissues to
determine age associated changes. Surrogate tissues and
ﬂuids such as human blood or urine are plentiful but are of
limitedvalueforassessingtissue-speciﬁceﬀects.Deﬁningthe
relationship between PGs, particularly PGI2 and PGH2,i n
vascular tissues and the amounts in blood or urine in an-
imal models could be helpful to interpret PG proﬁles in
humans. Technical challenges exist due to metabolite insta-
bility. For example, PGH2 is transformed to other PGs and
is biologically important in its own right, but untransformed
PGH2 is diﬃcult to measure [98, 245]. The development of
user-friendly methods could facilitate acquiring these meas-
urements [91, 98, 245]. For example, PGH2 can be instantly
reduced to 12-heptadecatrienoic acid (12-HHT) by FeCl2
[91, 98, 245]. 12-HHT is stable and inactive and measurable
[91, 98, 245]. Therefore, total PGH2 can be measured as 12-
HHT. A relatively mild reducing agent, SnCl2,c a nr e d u c e
untransformed PGH2 to PGF2α. Untransformed PGH2 can
becalculatedbysubtractingtheestimateofPGF2α insamples
without SnCl2 from the corresponding estimate in samples
with SnCl2 [91, 98, 125]. Alternatively, epidemiological ap-
proaches could avoid these technical diﬃculties and oﬀer
valuable genetic information. Haplotype analyses have re-
vealed that several polymorphisms in COX, PGIS, and IP are
associated with age and cardiovascular diseases [246–250].
Research on an important aspect of age-associated chan-
ges in PGs is largely absent in the literature; that of age-asso-
ciated eﬀects on PG metabolism. One of the most important
features of PGs is rapid clearance. Most PGs are metabolized
to inactive forms within 1–3 minutes [119, 251], and conse-
quently their signaling is terminated within that time frame.
This is due to an eﬀective and eﬃcient metabolism system
mainly composed of prostaglandin transporter (PGT) and
15-hydroxyprostaglandin dehydrogenase (15-PGDH) [252].
Both PGT and 15-PGDH have been shown to regulate PG
degradation [245, 253, 254]. Thus far, there have been no
reports on the inﬂuence of age on PG metabolism.
In conclusion, PGs and TxA2 play critical roles in many
important events involved in the normal functions of vas-
cular system, including vasodilation, vasoconstriction, plate-
let aggregation, and inﬂammation. Although these eicos-
anoids were discovered in the 1970s, the research into age-
associated shifts of the PG proﬁle has just begun. Age-asso-
ciated alterations in PG proﬁles are not only interesting, but
alsoimportantindeﬁningthemolecularmechanismsofage-
associated cardiovascular pathological conditions and in-
forming strategic and personalized prevention and cure of
those diseases.
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